Diagnostic Accuracy of MRI in Evaluating Response After Neoadjuvant Systemic Therapy in Operable Breast Cancer

被引:6
作者
Khazindar, Abdullah R. [1 ]
Hashem, Dalia Abdulmonem L. [2 ]
Abusanad, Atlal [3 ]
Bakhsh, Salwa, I [4 ]
Bin Mahfouz, Alya [5 ]
El-Diasty, Mohamed T. [5 ]
机构
[1] Univ Jeddah, Dept Radiol, Jeddah, Saudi Arabia
[2] King Faisal Specialist Hosp & Res Ctr, Dept Diagnost Radiol, Jeddah, Saudi Arabia
[3] King Abdulaziz Univ, Dept Med, Jeddah, Saudi Arabia
[4] King Abdulaziz Univ, Dept Pathol, Jeddah, Saudi Arabia
[5] King Abdulaziz Univ Hosp, Dept Radiol, Jeddah, Saudi Arabia
关键词
breast cancer; magnetic resonance imaging; complete pathological response; accuracy; radiological complete response; neoadjuvant chemotherapy; PATHOLOGICAL COMPLETE RESPONSE; CHEMOTHERAPY;
D O I
10.7759/cureus.15516
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Neoadjuvant chemotherapy (NAC) is an important step in the treatment of various types of breast cancer by downsizing the tumor to make it operable. Determining disease extent after NAC is essential for accurate surgical planning. MRI has been the gold standard for detecting tumors that are usually difficult to detect on ultrasound or mammography. However, the use of MRI after NAC is controversial. Therefore, we aimed to evaluate the diagnostic accuracy of post-NAC MRI in the detection of residual disease preoperatively and to investigate the factors associated with pathological complete response (pCR). Methodology This retrospective review study was approved by the institutional review board with waiving of the informed consent. A total of 90 charts between January 2016 and January 2019 were reviewed. Baseline lesion size was measured as the maximal diameter in a single dimension by pretreatment MRI. To assess the diagnostic accuracy of MRI in detecting residual disease, we used two different definitions of pCR in the breast. The first is the resolution of both invasive disease and ductal carcinoma in situ. The second is the resolution of the invasive disease only. As a secondary objective of the study, we assessed the association between different patients' characteristics and both MRI and pathologic response using univariate and multivariate analysis. Results A total of 52 women (mean age: 47.4 years; range: 28-74) with 56 breast masses were eligible for the study. Complete MRI response was noted in 22 ( 39%) masses. pCR was achieved in 14 (25%) and 25 (44.6%) masses using the first and second pCR definitions, respectively. The negative predictive value (NPV) and overall accuracy of MRI for detecting residual disease were 50% and 75%, respectively, using the first pCR definition. With the second pCR definition, NPV and accuracy were 77.3% and 76.8%, respectively. Positive axillary lymph nodes were the only significant factor associated with incomplete MRI and pathological responses. Conclusions MRI NPV for residual disease was higher with the second pCR definition; however, overall accuracy was not different. MRI accuracy in detecting residual disease after NAC is not adequate to replace pathological assessment.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Neoadjuvant Chemotherapy for Operable Breast Cancer: Individualizing Locoregional and Systemic Therapy
    Bear, Harry D.
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2010, 19 (03) : 607 - +
  • [2] Role of MRI to Assess Response to Neoadjuvant Therapy for Breast Cancer
    Reig, Beatriu
    Heacock, Laura
    Lewin, Alana
    Cho, Nariya
    Moy, Linda
    JOURNAL OF MAGNETIC RESONANCE IMAGING, 2020, 52 (06) : 1587 - 1606
  • [3] Effect of breast cancer phenotype on diagnostic performance of MRI in the prediction to response to neoadjuvant treatment
    Bufi, Enida
    Belli, Paolo
    Di Matteo, Marialuisa
    Terribile, Daniela
    Franceschini, Gianluca
    Nardone, Luigia
    Petrone, Gianluigi
    Bonomo, Lorenzo
    EUROPEAN JOURNAL OF RADIOLOGY, 2014, 83 (09) : 1631 - 1638
  • [4] MRI in diagnosis of pathological complete response in breast cancer patients after neoadjuvant chemotherapy
    Li, Yan-Ling
    Zhang, Xiao-Peng
    Li, Jie
    Cao, Kun
    Cui, Yong
    Li, Xiao-Ting
    Sun, Ying-Shi
    EUROPEAN JOURNAL OF RADIOLOGY, 2015, 84 (02) : 242 - 249
  • [5] The role of magnetic resonance imaging on evaluating response of neoadjuvant therapy for breast cancer
    Guo, Liang-cun
    Du, Si-yao
    Yang, Xiao-ping
    Li, Shu
    Zhang, Li-na
    CHINESE JOURNAL OF ACADEMIC RADIOLOGY, 2020, 3 (03) : 125 - 136
  • [6] Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer Translational Breast Cancer Research Consortium Trial 017
    De los Santos, Jennifer F.
    Cantor, Alan
    Amos, Keith D.
    Forero, Andres
    Golshan, Mehra
    Horton, Janet K.
    Hudis, Clifford A.
    Hylton, Nola M.
    McGuire, Kandace
    Meric-Bernstam, Funda
    Meszoely, Ingrid M.
    Nanda, Rita
    Hwang, E. Shelley
    CANCER, 2013, 119 (10) : 1776 - 1783
  • [7] Diagnostic accuracy of MRI to evaluate tumour response and residual tumour size after neoadjuvant chemotherapy in breast cancer patients
    Bouzon, Alberto
    Acea, Benigno
    Soler, Rafaela
    Iglesias, Angela
    Santiago, Paz
    Mosquera, Joaquin
    Calvo, Lourdes
    Seoane-Pillado, Teresa
    Garcia, Alejandra
    RADIOLOGY AND ONCOLOGY, 2016, 50 (01) : 73 - 79
  • [8] Neoadjuvant therapy for operable breast-cancer
    Insa, A
    Chirivella, I
    Lluch, A
    MEDICINA CLINICA, 2006, 126 (08): : 295 - 303
  • [9] Radiomics Based on DCE-MRI for Predicting Response to Neoadjuvant Therapy in Breast Cancer
    Zeng, Qiao
    Xiong, Fei
    Liu, Lan
    Zhong, Linhua
    Cai, Fengqin
    Zeng, Xianjun
    ACADEMIC RADIOLOGY, 2023, 30 : S38 - S49
  • [10] Diagnostic accuracy of contrast-enhanced mammography vs MRI in evaluating the response of breast cancer treated with neoadjuvant chemotherapy
    Lopez, Angela Iglesias
    Alejandro, Alberto Bouzon
    Lopez, Laura Abelairas
    Oses, Joaquin Jose Mosquera
    Romero, Jose Ramon Varela
    Chaves, Andres Vega
    REVISTA DE SENOLOGIA Y PATOLOGIA MAMARIA, 2023, 36 (01):